Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
This triple engagement distinguishes retatrutide from GLP-1 monoagonists like semaglutide or dual agonists like tirzepatide, potentially amplifying metabolic benefits across multiple organ systems including liver, pancreas, and central nervous appetite centers
It is reviewed periodically against current research
Foundayo/orforglipron trial results also showed clinically meaningful weight loss compared with placebo
4 The weight-loss efficacy of tirzepatide in both diabetic and non-diabetic individuals has been shown in the SURMOUNT trials
Most side effects involve the stomach and intestines, such as nausea or diarrhea
organ protective activity: protection of hepatic and pancreatic lesions, protection of endothelial cells, prevention of adhesion formation, prevention and treatment of myocardial infarction and brain stroke, protective effect in immune system
US$ 23.40
US$ 28.22
US$ 27.84
